EP2519519A4 - Substituted naphthalenyl-pyrimidine compounds - Google Patents

Substituted naphthalenyl-pyrimidine compounds

Info

Publication number
EP2519519A4
EP2519519A4 EP10841700.7A EP10841700A EP2519519A4 EP 2519519 A4 EP2519519 A4 EP 2519519A4 EP 10841700 A EP10841700 A EP 10841700A EP 2519519 A4 EP2519519 A4 EP 2519519A4
Authority
EP
European Patent Office
Prior art keywords
pyrimidine compounds
substituted naphthalenyl
naphthalenyl
substituted
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10841700.7A
Other languages
German (de)
French (fr)
Other versions
EP2519519A2 (en
Inventor
Mark A Ashwell
Chris Brassard
Audra Dalton
Jason Hill
Robert Nicewonger
David Vensel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of EP2519519A2 publication Critical patent/EP2519519A2/en
Publication of EP2519519A4 publication Critical patent/EP2519519A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP10841700.7A 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds Withdrawn EP2519519A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29091309P 2009-12-30 2009-12-30
PCT/US2010/062437 WO2011082268A2 (en) 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds

Publications (2)

Publication Number Publication Date
EP2519519A2 EP2519519A2 (en) 2012-11-07
EP2519519A4 true EP2519519A4 (en) 2013-04-24

Family

ID=44225054

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10841700.7A Withdrawn EP2519519A4 (en) 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds

Country Status (10)

Country Link
US (1) US8173808B2 (en)
EP (1) EP2519519A4 (en)
KR (1) KR20130005263A (en)
CN (1) CN102822169A (en)
AU (1) AU2010339531A1 (en)
CA (1) CA2788450A1 (en)
NZ (1) NZ601508A (en)
TW (1) TW201139410A (en)
WO (1) WO2011082268A2 (en)
ZA (1) ZA201205726B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
WO2011103289A2 (en) * 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
AR090037A1 (en) 2011-11-15 2014-10-15 Xention Ltd DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS
WO2014086453A1 (en) * 2012-12-07 2014-06-12 Merck Patent Gmbh Azaheterobicyclic compounds
CN104193644B (en) * 2014-09-27 2015-12-02 张远强 The succinamide derivative of methoxy naphthalene nucleus, Preparation Method And The Use
EP3371181A4 (en) * 2015-10-18 2019-10-16 Onco Therapies LLC Compositions and methods of regulating cancer related disorders and diseases
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
AU2022206470A1 (en) * 2021-01-07 2023-07-27 Ontario Institute For Cancer Research (Oicr) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026319A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE834993C (en) 1944-05-27 1952-03-27 Boehringer Sohn Ingelheim Process for the preparation of 2,6-Dioxy-4-aminopyrimidine-5-aminosulfonic acid in the form of its salts
GB681712A (en) 1949-09-14 1952-10-29 Burroughs Wellcome Co Improvements in or relating to therapeutically useful pyrimidine compounds
US2691655A (en) * 1952-05-24 1954-10-12 Burroughs Wellcome Co 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
DE4025891A1 (en) 1990-08-16 1992-02-20 Bayer Ag PYRIMIDYL-SUBSTITUTED ACRYLIC ACID ESTERS
JPH08503971A (en) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト Pyrimidineamine derivatives and methods for their preparation
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
KR100816769B1 (en) 2000-09-06 2008-03-26 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Inhibitors of glycogen synthase kinase 3
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
DE10133665A1 (en) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carboxylic acid derivatives, medicaments containing these compounds, their use and preparation
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
KR20040066296A (en) 2003-01-17 2004-07-27 주식회사 엘지생명과학 3-(2-amino-4-pyrimidinyl)-2-naphthol derivatives as inhibitors of cyclin dependent kinase
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP1644358A2 (en) 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005040135A1 (en) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
RU2007114080A (en) * 2004-10-13 2008-11-27 Вайет (Us) N-BENZylSULPHONIL-SUBSTITUTED ANALOGUES OF ANILINOPYRIMIDINE
US20080004271A1 (en) 2006-01-17 2008-01-03 Mckenna Jeffrey M Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith
DE102006008880A1 (en) 2006-02-27 2007-09-06 Merck Patent Gmbh aminopyrimidine derivatives
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
EP1903038A1 (en) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators
EP1903037A1 (en) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2008049749A1 (en) 2006-10-25 2008-05-02 Ciba Holding Inc. Heat-stable encapsulated pigments
JP4523073B2 (en) 2007-02-06 2010-08-11 ファイザー・インク 2-Amino-5,7-dihydro-6H-pyrrolo [3,4-d] pyrimidine derivatives as HSP-90 inhibitors for the treatment of cancer
US20100297009A1 (en) 2007-03-13 2010-11-25 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
AU2008228768A1 (en) 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated N-heterocyclic compounds useful as inhibitors of Janus Kinases
WO2008121570A1 (en) 2007-03-29 2008-10-09 Irm Llc Compounds and methods for modulating g protein-coupled receptors
KR20100016291A (en) * 2007-04-06 2010-02-12 노파르티스 아게 [2,6] naphthyridines useful as protein kinase inhibitors
DE102007017656A1 (en) 2007-04-12 2008-10-16 Henkel Ag & Co. Kgaa Biheteroaryl metal complexes as bleaching catalysts
US20080287452A1 (en) * 2007-05-16 2008-11-20 Wyeth Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009016564A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
DE602008004265D1 (en) 2007-07-27 2011-02-10 Actelion Pharmaceuticals Ltd TRANS-3-azabicyclo-Ä3.1.0Ü-HEXANE DERIVATIVES
US20090048282A1 (en) * 2007-08-14 2009-02-19 Wyeth Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026319A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DELACOTTE J-M ET AL: "Heterocycles with quinone function IX. Synthesis and cytotoxic activity of several 6-(4-pyrimidinyl)-1,4-naphthalenediones", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 22, no. 3, 1 May 1987 (1987-05-01), pages 187 - 192, XP023870991, ISSN: 0223-5234, [retrieved on 19870501], DOI: 10.1016/0223-5234(87)90048-1 *
PAWAN KALER ET AL: "The NF-[kappa]B/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1[beta]", CANCER MICROENVIRONMENT, vol. 2, no. 1, 1 December 2009 (2009-12-01), pages 69 - 80, XP055056689, ISSN: 1875-2292, DOI: 10.1007/s12307-009-0030-y *

Also Published As

Publication number Publication date
AU2010339531A1 (en) 2012-08-23
US8173808B2 (en) 2012-05-08
CA2788450A1 (en) 2011-07-07
CN102822169A (en) 2012-12-12
KR20130005263A (en) 2013-01-15
US20110166137A1 (en) 2011-07-07
ZA201205726B (en) 2013-09-25
WO2011082268A2 (en) 2011-07-07
WO2011082268A3 (en) 2011-10-20
NZ601508A (en) 2013-07-26
TW201139410A (en) 2011-11-16
EP2519519A2 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
ZA201107772B (en) Substituted spiro-amide compounds
EP2519525A4 (en) Substituted pyrrolo-aminopyrimidine compounds
EP2519522A4 (en) Substituted imidazopyridinyl-aminopyridine compounds
GB0907425D0 (en) Compounds
EP2393493A4 (en) Compounds
EP2491025A4 (en) Azaazulene compounds
GB0907515D0 (en) Compounds
GB0914856D0 (en) Compounds
GB0905641D0 (en) Compounds
ZA201205726B (en) Substituted naphthalenyl-pyrimidine compounds
GB0909671D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0915519D0 (en) Ntithrombotic compounds
GB0911000D0 (en) Compounds
GB0909672D0 (en) Compounds
EP2443115A4 (en) Compounds
GB0913248D0 (en) Compounds
GB0902391D0 (en) Compounds
GB0905057D0 (en) Compounds
GB0910675D0 (en) Compounds
GB0912238D0 (en) Compounds
GB0905054D0 (en) Compounds
GB0910008D0 (en) Compounds
GB0913753D0 (en) Compounds
GB0908941D0 (en) Compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120730

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130327

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 495/04 20060101ALI20130321BHEP

Ipc: A61K 31/53 20060101ALI20130321BHEP

Ipc: C07D 473/16 20060101ALI20130321BHEP

Ipc: C07D 239/42 20060101ALI20130321BHEP

Ipc: C07D 409/12 20060101ALI20130321BHEP

Ipc: A61K 45/06 20060101ALI20130321BHEP

Ipc: A61K 31/505 20060101ALI20130321BHEP

Ipc: A61K 31/5377 20060101ALI20130321BHEP

Ipc: C07D 401/12 20060101ALI20130321BHEP

Ipc: C07D 413/10 20060101ALI20130321BHEP

Ipc: C07D 409/14 20060101ALI20130321BHEP

Ipc: C07D 487/04 20060101ALI20130321BHEP

Ipc: A61P 35/00 20060101ALI20130321BHEP

Ipc: C07D 473/34 20060101ALI20130321BHEP

Ipc: C07D 401/14 20060101ALI20130321BHEP

Ipc: A61K 31/506 20060101ALI20130321BHEP

Ipc: C07D 403/12 20060101AFI20130321BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140701